Improving access to biosimilars and biologics
From Health Canada
This project will add to the review capacity for biosimilars and biologics by hiring more reviewers.
More review capacity through hiring of more reviewers to respond to the increase in drug submissions will result in:
- a more secure supply of biologic drugs with more than one manufacturer
- more affordable biologic drugs
- earlier access to new treatment options
We expect that all parts of the project will be fully in place by fall 2018.
Report a problem or mistake on this page
- Date modified: